Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management

Lin, 1985, Cloning and expression of the human erythropoietin gene, Proc Natl Acad Sci USA, 82, 7580, 10.1073/pnas.82.22.7580 Bokemeyer, 2004, EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer, Eur J Cancer, 40, 2201, 10.1016/j.ejca.2004.07.015 Egrie, 2003, Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin, Exp Hematol, 31, 290, 10.1016/S0301-472X(03)00006-7 Glaspy, 2002, Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy, Brit J Cancer, 87, 268, 10.1038/sj.bjc.6600465 Kotasek, 2003, Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study, Eur J Cancer, 39, 2026, 10.1016/S0959-8049(03)00456-8 Vansteenkiste, 2002, Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy, J Natl Cancer Inst, 94, 1211, 10.1093/jnci/94.16.1211 Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, Brit J Haematol, 122, 394, 10.1046/j.1365-2141.2003.04448.x Vansteenkiste, 2004, Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline, Support Care Cancer, 12, 253, 10.1007/s00520-003-0583-0 Glaspy, 2005, Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa, Eur J Cancer, 41, 1140, 10.1016/j.ejca.2005.01.021 Demetri, 1998, Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group, J Clin Oncol, 16, 3412, 10.1200/JCO.1998.16.10.3412 Osterborg, 2002, Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies, J Clin Oncol, 20, 2486, 10.1200/JCO.2002.08.131 Canon, 2006, Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy, J Natl Cancer Inst, 98, 274, 10.1093/jnci/djj053 Amgen Inc. Aranesp (Darbepoetin alfa) Package Insert 2005. Thousand Oaks, CA.